Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1996, Pages 497-506

  Hirschowitz, B I ^a   Mohnen, J ^a   Shaw, S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; LANSOPRAZOLE; PEPSIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; GASTRODUODENAL ULCER; HUMAN; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; ZOLLINGER ELLISON SYNDROME;

EID: 0030036159     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.11153000.x     Document Type: Article

References (18)

1. Hirschowitz BI. Clinical course of nonsurgically treated Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumours of the Pancreas - Recent Advances, Vol. 23 of Frontiers in Gastrointestinal Research series. Basel: S. Karger AG, 1994.
2. Jensen RT, Gardner JD, Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. In: Zakim D, Dannenberg AJ eds. Peptic Ulcer Disease and Other Acid-related Disorders. Armonk, New York: Academic Research Association, 1991: 117-212.
3. Kirkpatrick PM, Jr. Hirschowitz BI. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion. Gastroenterology 1980; 79: 4-10.
4. Hirschowitz BI. Apparent and intrinsic sensitivity to pentagastrin of acid and pepsin secretion in peptic ulcer. Gastroenterology 1984; 86: 843-51.
5. Hirschowitz BI, Groarke J. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls. Dig Dis Sci 1993; 38: 1874-84.
6. Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci 1994; 39: 1434-40.
7. Hirschowitz BI. High prevalence of esophagitis in Zollinger-Ellison syndrome vs. low prevalence in non-ZE DU with BAO > 15 mEq/h. Gastroenterology 1990; 98 (Suppl.): A59 (Abstract).
8. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-6.
9. Hirschowitz BI, Mohnen J, Shaw S. A prospective long-term study of lansoprazole for treatment of of Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 507-522.
10. Solcia E, Bordi C, Creutzfeld W, et al. Histopathological classification of non-antral gastric endocrine growths in man. Digestion 1988; 41: 185-200.
11. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.
12. Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989; 111: 713-22.
13. Hirschowitz BI, Molina E, Ou-Tim L, Helman CA. Effects of very low doses of atropine on basal and pepsin secretion, gastrin and heart rate in normals and DU. Dig Dis Sci 1984; 29: 790-6.
14. Pfeiffer A, Kromer W, Friemann J, et al. Muscarinis receptors in gastric mucosa are increased in peptic ulcer disease. Gut 1995; 36: 813-8.
15. Saeed ZA, Evans DJ, Jr. Evans DG, et al. Helicobacter pylori and Zollinger-Ellison syndrome. Dig Dis Sci 1991; 36: 15-8.
16. Metz DC, Weber HC, Orbuch M, et al. Helicobacter pylori infection. A reversible cause of hypergastrinemia and hyperchlorhydria which may mimic Zollinger-Ellison syndrome. Dig Dis Sci 1995; 40: 153-9.
17. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
18. Larner AJ, Hamilton MIR. Review article: infective complications of therapeutic gastric acid inhibition. Aliment Pharmacol Ther 1994; 8: 574-84.